This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (17)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Public Health  • Obesity  • Alert me on articles by topic  Social Bookmarking   What's this?

A Report of 3 Cases

Jouko I. T. Isojärvi, MD, PhD; Juha S. Tapanainen, MD, PhD

Arch Neurol. 2000;57:1064-1068.

Background  Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.

Objective  To describe the development of valproate-related reproductive endocrine disorders in women with epilepsy.

Design  Case report.

Patients  Three patients developed a reproductive endocrine disorder during treatment with valproate. It was characterized by hyperandrogenism and polycystic ovaries in all cases, and it was associated with weight gain and menstrual disorders in 2 of the 3 women.

Results  Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women. The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.

Conclusions  The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy. The disorders were characterized by hyperandrogenism and polycystic ovaries in all cases, and were associated with weight gain and menstrual disorders in 2 of the 3 women. An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment.

From the Departments of Neurology (Dr Isojärvi) and Obstetrics and Gynecology (Dr Tapanainen), University of Oulu, Oulu, Finland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(7):1089-1090.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Valproate Potentiates Androgen Biosynthesis in Human Ovarian Theca Cells
Nelson-DeGrave et al.
Endocrinology 2004;145:799-808.
ABSTRACT | FULL TEXT